Cargando…
Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596628/ https://www.ncbi.nlm.nih.gov/pubmed/36107308 http://dx.doi.org/10.1007/s41669-022-00372-0 |
| _version_ | 1784815913034317824 |
|---|---|
| author | Elsea, David Fan, Lin Mihai, Adela Moustaid, Fadoua El Simmons, Daniel Monberg, Matthew Muston, Dominic |
| author_facet | Elsea, David Fan, Lin Mihai, Adela Moustaid, Fadoua El Simmons, Daniel Monberg, Matthew Muston, Dominic |
| author_sort | Elsea, David |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9596628 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-95966282022-10-27 Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer Elsea, David Fan, Lin Mihai, Adela Moustaid, Fadoua El Simmons, Daniel Monberg, Matthew Muston, Dominic Pharmacoecon Open Correction Springer International Publishing 2022-09-15 /pmc/articles/PMC9596628/ /pubmed/36107308 http://dx.doi.org/10.1007/s41669-022-00372-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Correction Elsea, David Fan, Lin Mihai, Adela Moustaid, Fadoua El Simmons, Daniel Monberg, Matthew Muston, Dominic Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer |
| title | Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer |
| title_full | Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer |
| title_fullStr | Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer |
| title_full_unstemmed | Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer |
| title_short | Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer |
| title_sort | correction to: cost-effectiveness analysis of olaparib in combination with bevacizumab compared with bevacizumab monotherapy for the first-line maintenance treatment of homologous recombination deficiency-positive advanced ovarian cancer |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596628/ https://www.ncbi.nlm.nih.gov/pubmed/36107308 http://dx.doi.org/10.1007/s41669-022-00372-0 |
| work_keys_str_mv | AT elseadavid correctiontocosteffectivenessanalysisofolaparibincombinationwithbevacizumabcomparedwithbevacizumabmonotherapyforthefirstlinemaintenancetreatmentofhomologousrecombinationdeficiencypositiveadvancedovariancancer AT fanlin correctiontocosteffectivenessanalysisofolaparibincombinationwithbevacizumabcomparedwithbevacizumabmonotherapyforthefirstlinemaintenancetreatmentofhomologousrecombinationdeficiencypositiveadvancedovariancancer AT mihaiadela correctiontocosteffectivenessanalysisofolaparibincombinationwithbevacizumabcomparedwithbevacizumabmonotherapyforthefirstlinemaintenancetreatmentofhomologousrecombinationdeficiencypositiveadvancedovariancancer AT moustaidfadouael correctiontocosteffectivenessanalysisofolaparibincombinationwithbevacizumabcomparedwithbevacizumabmonotherapyforthefirstlinemaintenancetreatmentofhomologousrecombinationdeficiencypositiveadvancedovariancancer AT simmonsdaniel correctiontocosteffectivenessanalysisofolaparibincombinationwithbevacizumabcomparedwithbevacizumabmonotherapyforthefirstlinemaintenancetreatmentofhomologousrecombinationdeficiencypositiveadvancedovariancancer AT monbergmatthew correctiontocosteffectivenessanalysisofolaparibincombinationwithbevacizumabcomparedwithbevacizumabmonotherapyforthefirstlinemaintenancetreatmentofhomologousrecombinationdeficiencypositiveadvancedovariancancer AT mustondominic correctiontocosteffectivenessanalysisofolaparibincombinationwithbevacizumabcomparedwithbevacizumabmonotherapyforthefirstlinemaintenancetreatmentofhomologousrecombinationdeficiencypositiveadvancedovariancancer |